These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

238 related items for PubMed ID: 29360439

  • 1. Dihydroartemisinin suppresses STAT3 signaling and Mcl-1 and Survivin expression to potentiate ABT-263-induced apoptosis in Non-small Cell Lung Cancer cells harboring EGFR or RAS mutation.
    Yan X, Li P, Zhan Y, Qi M, Liu J, An Z, Yang W, Xiao H, Wu H, Qi Y, Shao H.
    Biochem Pharmacol; 2018 Apr; 150():72-85. PubMed ID: 29360439
    [Abstract] [Full Text] [Related]

  • 2. Dihydroartemisinin inhibits tumor progress via blocking ROR1-induced STAT3-activation in non-small cell lung cancer.
    Li Y, Sun H, Bai C, Hu Y, Tang J, Zhang Y, Chen J, Zhong Z, He Y, Hu K, Yang J.
    Int Immunopharmacol; 2024 May 30; 133():112157. PubMed ID: 38678671
    [Abstract] [Full Text] [Related]

  • 3. Modulation of Navitoclax Sensitivity by Dihydroartemisinin-Mediated MCL-1 Repression in BCR-ABL+ B-Lineage Acute Lymphoblastic Leukemia.
    Budhraja A, Turnis ME, Churchman ML, Kothari A, Yang X, Xu H, Kaminska E, Panetta JC, Finkelstein D, Mullighan CG, Opferman JT.
    Clin Cancer Res; 2017 Dec 15; 23(24):7558-7568. PubMed ID: 28974549
    [Abstract] [Full Text] [Related]

  • 4. ABT-737 Synergizes with Cisplatin Bypassing Aberration of Apoptotic Pathway in Non-small Cell Lung Cancer.
    Kim EY, Jung JY, Kim A, Chang YS, Kim SK.
    Neoplasia; 2017 Apr 15; 19(4):354-363. PubMed ID: 28319809
    [Abstract] [Full Text] [Related]

  • 5. Cyclosporine A sensitizes human non-small cell lung cancer cells to gefitinib through inhibition of STAT3.
    Shou J, You L, Yao J, Xie J, Jing J, Jing Z, Jiang L, Sui X, Pan H, Han W.
    Cancer Lett; 2016 Aug 28; 379(1):124-33. PubMed ID: 27264264
    [Abstract] [Full Text] [Related]

  • 6. Cafestol overcomes ABT-737 resistance in Mcl-1-overexpressed renal carcinoma Caki cells through downregulation of Mcl-1 expression and upregulation of Bim expression.
    Woo SM, Min KJ, Seo BR, Nam JO, Choi KS, Yoo YH, Kwon TK.
    Cell Death Dis; 2014 Nov 06; 5(11):e1514. PubMed ID: 25375379
    [Abstract] [Full Text] [Related]

  • 7. YM-155 potentiates the effect of ABT-737 in malignant human glioma cells via survivin and Mcl-1 downregulation in an EGFR-dependent context.
    Jane EP, Premkumar DR, DiDomenico JD, Hu B, Cheng SY, Pollack IF.
    Mol Cancer Ther; 2013 Mar 06; 12(3):326-38. PubMed ID: 23325792
    [Abstract] [Full Text] [Related]

  • 8. Continuous exposure of non-small cell lung cancer cells with wild-type EGFR to an inhibitor of EGFR tyrosine kinase induces chemoresistance by activating STAT3.
    Tang J, Guo F, Du Y, Liu X, Qin Q, Liu X, Yin T, Jiang L, Wang Y.
    Int J Oncol; 2015 May 06; 46(5):2083-95. PubMed ID: 25695284
    [Abstract] [Full Text] [Related]

  • 9. The Ibr-7 derivative of ibrutinib exhibits enhanced cytotoxicity against non-small cell lung cancer cells via targeting of mTORC1/S6 signaling.
    Zhang B, Wang L, Zhang Q, Yan Y, Jiang H, Hu R, Zhou X, Liu X, Feng J, Lin N.
    Mol Oncol; 2019 Apr 06; 13(4):946-958. PubMed ID: 30663221
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Combination of onconase and dihydroartemisinin synergistically suppresses growth and angiogenesis of non-small-cell lung carcinoma and malignant mesothelioma.
    Shen R, Li J, Ye D, Wang Q, Fei J.
    Acta Biochim Biophys Sin (Shanghai); 2016 Oct 06; 48(10):894-901. PubMed ID: 27590062
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. CM082, a novel angiogenesis inhibitor, enhances the antitumor activity of gefitinib on epidermal growth factor receptor mutant non-small cell lung cancer in vitro and in vivo.
    Zhang K, Wang L, Wei A, Jia X, Liu X.
    Thorac Cancer; 2020 Jun 06; 11(6):1566-1577. PubMed ID: 32368855
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.